TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19458488

Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (0.2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (0.6 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VCL‐AB01 (0.6 mg) in nonhuman primates
Number of subjects: 0
Study: 17536922

Group type: EXPERIMENTAL
Intervention: School nurses providing PCPs with accurate peak flow data and requesting an AAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: School nurses requesting an AAP via the students' parents without providing peak flow data
Number of subjects: 0
Study: 15370062

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 190
Study: 11747385

Group type: EXPERIMENTAL
Intervention: Prophylactic use of beta-adrenergic blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic amiodarone and atrial overdrive pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhythm management (electrical cardioversion, amiodarone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0
Study: 9576151

Group type: EXPERIMENTAL
Intervention: Chronic stable angina
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Diabetics with elevated total and LDL cholesterol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 58

Group type: COMPARATOR
Intervention: Patients with stable angina
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Diabetics with markedly abnormal peripheral reflexes
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Standard tests of autonomic function
Number of subjects: 58
Study: 7886749

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo-treated bed nets
Number of subjects: 6
Study: 2905252

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 75 mg twice daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg at bedtime
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ranitidine 300 mg at night
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg post cenam nocte (PCN)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ranitidine 300 mg post cenam nocte (PCN)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 300 mg post cenam nocte (PCN)
Number of subjects: 59
Study: 29404770

Group type: EXPERIMENTAL
Intervention: Sn100kVp acquisition
Number of subjects: 78

Group type: COMPARATOR
Intervention: 120kVp acquisition
Number of subjects: 78
Study: 28259610

Group type: EXPERIMENTAL
Intervention: Vandetanib plus gemcitabine
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 142
Study: 26151176

Group type: EXPERIMENTAL
Intervention: Mobile Food Record (mFR) application for dietary assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediction model for a Healthy and Sustainable Diet Index
Number of subjects: 0
Study: 24481570

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean final dose 14.4 mg/day)
Number of subjects: 68
Study: 22104618

Group type: EXPERIMENTAL
Intervention: Gemcitabine with bevacizumab
Number of subjects: 267

Group type: COMPARATOR
Intervention: Gemcitabine with placebo
Number of subjects: 267
Study: 19577277

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy (at least 5 cycles)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting median survival and 5-year survival probability
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy
Number of subjects: 367
Study: 17578360

Group type: EXPERIMENTAL
Intervention: DA-3801
Number of subjects: 97
Study: 15215806

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.5)
Number of subjects: 279

Group type: COMPARATOR
Intervention: No antithrombotic treatment
Number of subjects: 279
Study: 11222822

Group type: EXPERIMENTAL
Intervention: Various drugs used for disease control during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy counselling and collaboration with obstetricians and perinatologists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fertility rate and optimal timing of conception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk of disease flares during lupus pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnancy course and fetal outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contraceptive advice
Number of subjects: 0
Study: 10765970

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9221559

Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 38

Group type: COMPARATOR
Intervention: Peroral chemotherapy (Hydroxyurea or Busulphan)
Number of subjects: 38
Study: 2139409

Group type: EXPERIMENTAL
Intervention: 100 mg/d Gallopamil (group 1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 200 mg/d Metoprolol (group 2)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 50 mg Atenolol and 20 mg Nifedipine daily (group 3)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 200 mg Acebutolol plus 20 mg Nifedipine daily (group 4)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 50 mg Atenolol plus 10 mg Enalapril daily (group 5)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 117
Study: 7247639

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy and behavior therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Behavior therapy alone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 120
Study: 31567411

Group type: EXPERIMENTAL
Intervention: Oral fosfomycin monotherapy for uncomplicated UTI and bacterial prostatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin in combination with other agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fosfomycin (specific details not provided)
Number of subjects: 0
Study: 27095167

Group type: EXPERIMENTAL
Intervention: Estazolam
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 26775373

Group type: EXPERIMENTAL
Intervention: Tramadol (75 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tramadol + Gabapentin (75 mg/day tramadol + 900 mg/day gabapentin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Tramadol only)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental group (Tramadol + Gabapentin)
Number of subjects: 40
Study: 25881758

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (waiting list under drug treatment)
Number of subjects: 61
Study: 24311316

Group type: EXPERIMENTAL
Intervention: S. boulardii 500 mg/day + AB
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: S. boulardii + ORS
Number of subjects: 333
Study: 21554803

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (mean 30 % weight loss)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duodenal switch surgery (mean 41 % weight loss)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy persons (BMI 17‐31 kg/m(2))
Number of subjects: 60
Study: 18647982

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg adjustable to 100 mg before sexual activity)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sildenafil and Placebo
Number of subjects: 98
Study: 16575013

Group type: EXPERIMENTAL
Intervention: Immediate counseling
Number of subjects: 60
Study: 14740953

Group type: EXPERIMENTAL
Intervention: Monovalent live‐attenuated dengue virus (DENV) vaccine candidates
Number of subjects: 69
Study: 10674459

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection at a dosage of 0.1 mmol/kg body weight
Number of subjects: 59

Group type: COMPARATOR
Intervention: No contrast (control group)
Number of subjects: 59
Study: 9846855

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (200,000 IU; 100,000 IU if aged <12 mo)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin A (5000 IU/d until discharge)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 900
Study: 7905256

Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine hydrochloride (mean, 233 +/- 72 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo substitution
Number of subjects: 24
Study: 2645914

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg tid
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg tid
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg tid and Propranolol 40 mg tid
Number of subjects: 234
Study: 1097295

Group type: EXPERIMENTAL
Intervention: Azathioprine (1.5 mg per kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31027246

Group type: EXPERIMENTAL
Intervention: Caffeinated gel (300 mg of caffeine)
Number of subjects: 17
Study: 28974184

Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Minimal supportive treatment/waitlist control
Number of subjects: 93
Study: 26089546

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline-sham
Number of subjects: 38
Study: 23473396

Group type: EXPERIMENTAL
Intervention: Fibrinolysis with bolus tenecteplase (half dose for patients ≥75 years), clopidogrel, and enoxaparin before transport to a PCI-capable hospital.
Number of subjects: 1892

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1892

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1892
Study: 21554679

Group type: EXPERIMENTAL
Intervention: IV infusion of salbutamol (15 μg kg ideal body weight‐1 hr‐1)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 1334
Study: 17852392

Group type: EXPERIMENTAL
Intervention: High-dose NovaSil (3.0 g NS day(-1))
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Low-dose NovaSil (1.5 g NS day(-1))
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo-control (0 g NS day(-1))
Number of subjects: 177
Study: 16715252

Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3%
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.5%
Number of subjects: 16
Study: 14579081

Group type: EXPERIMENTAL
Intervention: Whole-body PET
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional work-up (CWU)
Number of subjects: 188
Study: 10707753

Group type: EXPERIMENTAL
Intervention: GIK infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 21
Study: 9112894

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 83
Study: 7814116

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) technique
Number of subjects: 3

Group type: COMPARATOR
Intervention: Restorative care (amalgam fillings)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 2735592

Group type: EXPERIMENTAL
Intervention: 20 mL/kg normal saline infusion over 45 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15 mL/kg normal saline infusion over one hour (after first infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 20 mL/kg normal saline infusion over 45 minutes (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 15 mL/kg normal saline infusion over three hours (after first infusion)
Number of subjects: 20
Study: 31784345

Group type: EXPERIMENTAL
Intervention: Saury oil (12 g; 3.5 g of LCMUFA and 3.4 g of omega-3 FAs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Saury oil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control oil (identical capsules with a mixture of sardine and olive oil; 4.9 g of shorter-chain MUFA oleate and 3 g of omega-3 FAs)
Number of subjects: 30
Study: 31062094

Group type: EXPERIMENTAL
Intervention: Lymphocyte-monocyte-neutrophil score (LMN score) based on preoperative absolute counts of neutrophils, lymphocytes, and monocytes.
Number of subjects: 445
Study: 27229178

Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin fixed-dose combination (Sita/Met)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 292
Study: 25487222

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography guidance
Number of subjects: 101

Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 101
Study: 23337655

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 47
Study: 22040190

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 18436340

Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview
Number of subjects: 494

Group type: COMPARATOR
Intervention: Discharge Instructions
Number of subjects: 494
Study: 16494088

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 35
Study: 12917228

Group type: EXPERIMENTAL
Intervention: Early diagnosis (screened) group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 10688506

Group type: EXPERIMENTAL
Intervention: 100 microg misoprostol orally every 4 hours to a maximum of three doses
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion according to the hospital protocol
Number of subjects: 80
Study: 9352869

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN-alpha (higher dosage and longer period)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid IFN-alpha (same schedule)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Initial nonresponders (no retreatment)
Number of subjects: 92
Study: 1386386

Group type: EXPERIMENTAL
Intervention: Psychosocial factors assessed at the beginning of the study
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Self-employment
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Free-floating anxiety
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Internal back pain locus of control
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Beliefs in control by others
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Accomplishment of back exercises
Number of subjects: 476
Study: 4070645

Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 34
Study: 31423687

Group type: EXPERIMENTAL
Intervention: Chemical cardioversion with procainamide infusion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 84
Study: 29631782

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous every 6 months)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Risedronate (5 mg oral daily)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Both Denosumab and Risedronate
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 795
Study: 27876038

Group type: EXPERIMENTAL
Intervention: Perceived availability of built environment structures
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Perceived condition of built environment structures
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Perceived safety of built environment structures
Number of subjects: 610
Study: 23597109

Group type: EXPERIMENTAL
Intervention: 20 mg/day citalopram for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 0
Study: 22677878

Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Number of subjects: 130

Group type: COMPARATOR
Intervention: McGrath videolaryngoscope
Number of subjects: 130
Study: 20626147

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with small dose of clozapine (50 mg/d to 100‐150 mg/d, 3 times a week for 8 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional oral administration of clozapine (50‐100 mg/d to 200‐500 mg/d, for 8 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with small dose of clozapine
Number of subjects: 80
Study: 19093056

Group type: EXPERIMENTAL
Intervention: Mandibular 2-implant overdenture (IOD)
Number of subjects: 162

Group type: COMPARATOR
Intervention: New conventional denture (CD)
Number of subjects: 162
Study: 16224525

Group type: EXPERIMENTAL
Intervention: Propofol combined with epidural block
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (plasma concentration 4 microg/L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (plasma concentration 7 microg/L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion using propofol with Marsh parameters
Number of subjects: 30
Study: 12005077

Group type: EXPERIMENTAL
Intervention: Milk basic protein (MBP) 40 mg per day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10068928

Group type: EXPERIMENTAL
Intervention: UVA1 therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: UVA1 cold light therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Combined UVA-UVB therapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: UVA1 therapy (4 weeks post-treatment)
Number of subjects: 70

Group type: COMPARATOR
Intervention: UVA-UVB therapy
Number of subjects: 70
Study: 7586348

Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz coronary stent implantation
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 207
Study: 2405291

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 7
Study: 6764120

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 111

Group type: COMPARATOR
Intervention: OK-432
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study: 31706550

Group type: EXPERIMENTAL
Intervention: Conventional intervention (pediatric-focused posters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Front-line ownership (FLO) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLO intervention
Number of subjects: 0
Study: 31148155

Group type: EXPERIMENTAL
Intervention: Amustaline-Glutathione (A-GSH) RBCC
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control RBCC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: A-GSH RBCC
Number of subjects: 80

Group type: COMPARATOR
Intervention: A-GSH RBCC and Control RBCC
Number of subjects: 80
Study: 28419855

Group type: EXPERIMENTAL
Intervention: Silymarin (700 mg, 3 times daily for 48 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 25791707

Group type: EXPERIMENTAL
Intervention: Sodium alendronate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 26030948

Group type: EXPERIMENTAL
Intervention: Combination therapy of ultrasound and TENS
Number of subjects: 115

Group type: COMPARATOR
Intervention: Monotherapy (either ultrasound or TENS)
Number of subjects: 115
Study: 20857170

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg PO daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19500005

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with drugs
Number of subjects: 537
Study: 17434599

Group type: EXPERIMENTAL
Intervention: Mood stabilizer treatment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Bipolar manic patients
Number of subjects: 111
Study: 15078000

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg)
Number of subjects: 12
Study: 11214127

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg as needed
Number of subjects: 362

Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg as needed
Number of subjects: 362
Study: 9453275

Group type: EXPERIMENTAL
Intervention: Severe attack definition
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Migraine sufferers with at least one severe attack
Number of subjects: 276
Study: 7938398

Group type: EXPERIMENTAL
Intervention: Sublingual captopril
Number of subjects: 12
Study: 3340574

Group type: EXPERIMENTAL
Intervention: Intensity-controlled, graded dance exercise with individual and group reinforcement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Moderate intensity exercise typical of commercial fitness classes with no special reinforcement
Number of subjects: 38
Study: 29452110

Group type: EXPERIMENTAL
Intervention: Screening doors and windows with wire meshes in 46 houses
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study: 27267081

Group type: EXPERIMENTAL
Intervention: Erlotinib monotherapy
Number of subjects: 177
Study: 25850968

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day (monotherapy)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day + Metformin ≥1500 mg/day (add-on therapy)
Number of subjects: 411
Study: 23349117

Group type: EXPERIMENTAL
Intervention: Physical model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Textbooks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3D computer model
Number of subjects: 0